about
New aspects in the management of pneumoniaTreatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study.New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality: A Validation and Clinical Decision-making Study.Clinical Management of Community Acquired Pneumonia in the Elderly Patient.Evaluation of the 2016 Infectious Diseases Society of America/American Thoracic Society Guideline Criteria for Risk of Multi-drug Resistant Pathogens in Hospital-acquired and Ventilator-associated Pneumonia Patients in the Intensive Care Unit.Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia.Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia.Rapid identification of antimicrobial resistance patterns allows a faster antibiotic adequacy.Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality.37th International Symposium on Intensive Care and Emergency Medicine (part 3 of 3): Brussels, Belgium. 21-24 March 2017.Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia.Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis.Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease.Usefulness of Adenosine Deaminase Assay in Diagnosis of Patients with HIV Infection and Pleural TuberculosisAn international perspective on hospitalized patients with viral community-acquired pneumoniaScore for Differentiating Pleural Tuberculosis from Malignant EffusionEffect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired PneumoniaTwenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumoniaSepsis and community-acquired pneumoniaAdjunctive Therapies for Community-Acquired PneumoniaAntimicrobial Resistance Among Streptococcus pneumoniaeAntimicrobial Treatment of CAP. Is there a higher benefit of macrolides combination in patients with pneumococcal CAP?Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumoniaMicrobiological vs non-microbiological confirmed nnventilator ICU-acquired pneumoniaUsefulness of real time-polymerase chain reaction (RT-PCR) in the diagnosis of ICU-acquired pneumonia (ICUAP)A new wave of influenza A: Description of a cohort of patients in 2013 from a general hospital in Buenos Aires, ArgentinaBronchiectasis in rare pulmonary diseases: A case seriesSevere community-acquired pneumoniaInvasive and non-invasive diagnostic approaches for microbiological diagnosis of hospital-acquired pneumoniaVentilator-associated pneumonia: new principles guiding empiric antibiotic therapyEffect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of LymphopeniaComparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patientsAssessment of a Loop-Mediated Isothermal Amplification (LAMP) Assay for the Rapid Detection of Pathogenic Bacteria from Respiratory Samples in Patients with Hospital-Acquired PneumoniaLymphocytopenia as a Predictor of Mortality in Patients with ICU-Acquired PneumoniaESICM LIVES 2016: part one: Milan, Italy. 1-5 October 2016Difficult to Treat Microorganisms in Patients Over 80 Years with Community-Acquired Pneumonia: The Prevalence of PES Pathogens
P50
Q28080025-BBE709AA-D23B-41D6-89BF-AAE7582602B0Q36406243-498F1277-3A5A-454A-A516-72FA0BBC8BC8Q38402197-3FA9A3A4-508B-4807-BBF4-B08E6D1549DAQ38725994-E6AE20B0-A2FA-4816-8594-EBE38F14B213Q38969066-F6164998-1FDD-458F-A5F2-8B0CBBD81EEFQ40049111-6B1F3306-55A9-4C91-B8FD-45CE1BB86EB7Q40102140-28F8941D-F1AD-4CF7-8446-8428BF2A57E1Q40369913-DFBC6483-C906-477A-8B34-0984CA9A886EQ42343353-9B851847-83E4-4984-9F97-AD664BB3CA29Q42651370-CC8569C8-1547-45D8-9F0E-519A7C3D15FFQ46439045-F6C79F90-763B-4BE7-A1D0-251F59ACB596Q52807449-D8DDCAD3-7DDB-42EE-8FE3-7B425339CB8FQ55299717-FC79541F-6B3E-473B-B6FC-C9A1F429A2B0Q55400934-4564F865-A870-4625-8996-8D257B07A5E0Q59351034-FDEAEF46-084A-4B84-AF04-170BB45DA9DFQ59432680-659D645A-C2D8-47CD-AB9C-CD531474116BQ64102135-DBE5B659-4426-4766-A2C5-F9E4C79E732FQ64134858-6CD1DBB1-9F38-4AE1-A11A-4F2C0CEB3C76Q64134862-5280E043-B56E-4FB5-8F77-E9D063C94048Q64134865-A86E6C95-07FF-4BD8-B59D-942F43761C22Q64134870-80015B16-8008-411B-B66A-BABEB6B13BBCQ64134873-23BF594C-7854-4F23-8A0E-A1C8EEB99F81Q64134875-8A0C0DC4-A6C6-4EDF-97C4-7CA137933D23Q64134881-882DB1C1-6D86-4777-A0EE-26F2047027A7Q64134884-9D29595A-4BE1-4D1D-8F48-FA5ED864FC50Q64134887-5C9060F8-FA5D-43E7-9E9F-0A820B0548B1Q64134889-F20575DA-673E-4401-841E-75A32AFA916BQ64134892-8BD9792C-45C6-42A5-9C93-FED1B751B078Q64134894-361A211E-214A-41C8-A174-A6E533BF593EQ64254525-9CE591D6-344A-4AEF-B928-F26F09C547F8Q89545017-CE287737-4C3A-4CD3-8762-483B26CA8C41Q90194219-B4D78C8B-DDA6-4F8F-861A-95D1032F023CQ91773983-DE57D913-6532-4A4F-99E6-4A8C551BC76FQ92661127-E673A165-9A17-40C9-B115-BC39DDDBCF69Q92755481-0DA1E100-4311-44E0-884C-50D3266F249AQ93951547-AD737057-62E8-4B2C-9D7D-A29667F6ABDFQ95268187-7643DAB0-E4D8-4D57-B24F-4AD071A711E1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Adrian Ceccato
@ast
Adrian Ceccato
@en
Adrian Ceccato
@es
Adrian Ceccato
@nl
type
label
Adrian Ceccato
@ast
Adrian Ceccato
@en
Adrian Ceccato
@es
Adrian Ceccato
@nl
prefLabel
Adrian Ceccato
@ast
Adrian Ceccato
@en
Adrian Ceccato
@es
Adrian Ceccato
@nl
P106
P1153
56349658400
P21
P31
P496
0000-0001-9454-062X